Predictive Factors and Risk Model for Positive Circumferential Resection Margin Rate After Transanal Total Mesorectal Excision in 2653 Patients With Rectal Cancer

Sapho X Roodbeen,F B de Lacy,Susan van Dieren,Marta Penna,Frédéric Ris,Brendan Moran,Paris Tekkis,Willem A Bemelman,Roel Hompes,International TaTME Registry Collaborative,Michel Adamina,Felix Aigner,Hazar Al Furajii,Benjamin Albers,Andrew S Allison,Alberto Arezzo,Steven J Arnold,Kamal Aryal,Sam Atallah,Ralph Austin,Mirza Khurrum Baig,Ioannis Baloyiannis,Dibyendu Bandyopadhyay,Saswata Banerjee,Balazs Banky,Joerg Baral,Eric Belgers,Stephen Bell,Stefano Berti,Matthias Biebl,Bobby Bloemendaal,Luigi Boni,Liliana Bordeianou,Dario Borreca,Robbert J I Bosker,Benjamin Box,Stephen Boyce,Raquel Bravo,Sylvie van den Broeck,Carl Brown,Lukas Bruegger,Walter Brunner,Christian Buchli,Nicolas C Buchs,Alexander Buia,Caroline Burt,Ronan Cahill,Juan Pablo Campana,Kenneth Campbell,Francesca Di Candido,Gabriella T Capolupo,Marco Caricato,Aleidis Caro-Tarrago,Elisa Cassinotti,Antonio Caycedo,Pramodh Chandrasinghe,Sanjay Chaudhri,Stanislav Chernyshov,Praminthra Chitsabesan,Dimitri Christoforidis,David A Clark,Julien Coget,Edward D Courtney,Chris Cunningham,Pieter D’Hooge,Andre D’Hoore,Francois Dagbert,Stephen J Dalton,Giovanni Dapri,Robin Dawson,Sanjeev Dayal,Salvadora Delgado,Paolo Delrio,Johannes Doerner,Pascal Doornebosch,Sarah Duff,Khasan Erkinovich Dzhumabaev,Tom Edwards,Monika Egenvall,Jens Ravn Eriksen,Eloy Espin,Lope Estevez-Schwarz,Seraina Faes,Arne Fearden,Cosimo Feleppa,Tim Forgan,Havard Forsmo,Nader K Francis,Alice Frontali,Cherylin Fu,Bawantha Gamage,Jose Ignacio Rodriguez Garcia,Daniel Geissmann,Bart van Geluwe,Kathryn Gill,Markus Glockler,Severin Gloor,Carlos Javier Gomez,Eelco de Graaf,Tomas Grolich,Jutten Guido,Dieter Hahnloser,Julian Hance,Athur Harikrishnan,Ingrid Haunold,Julian Hayes,Tom Hendrickx,Alexander Heriot,Theo-Julian Hoffmann,Yao HongWei,Joe Huang,Horwood James,Roshan Ial,Masaaki Ito,Marc Janssens,Howard Joy,Guilherme Pagin Sao Juliao,Ahmer Karimuddin,Mark Katory,Shane Killeen,Werner Kneist,Joep Knol,Niels Komen,Neil Kukreja,Miranda Kusters,Antonio de Lacy,Lorand Lakatos,Anton Lambrechts,Carlos Alvarez Laso,Pedro Leao,Emanuele Lezoche,Sender A Liberman,Paul Lidder,Meylina Andrade Lima,Laura Lorenzon,Paul Mackey,Leon Maggiori,Zaman Zaur Mamedli,Steve Mansfield,Steven Marcoen,Tobias Marcy,Tohmeh Maroon,Damieta Marta Pascual,Lukas Marti,Sushil Maslekar,Iain McCallum,Kathryn McCarthy,Carlos Ramon Silveira Mendes,Arend Merrie,Antonios Michalopoulos,Saulius Mikalauskas,Anthony W F Miles,Sarah C Mills,Yevgen Miroshnychenko,Christof Mittermair,Richard Molloy,Isacco Montroni,Etienne Moore,Tim Moore,Barbara Mooslechner,Mario Morino,Gabriela Moslein,Andrea Muratore,Ventsislav Metodiev Mutafchiyski,Alistair Myers,Deborah Nicol,Yves van Nieuwenhove,Daisuke Nishizaki,Gregory John Nolan,Alex Ochsner,Jae Hwan Oh,Pablo Collera Ormazabal,Ana Otero,Susana Ouro,Yves Panis,Theodosios Papavramidis,Michael von Papen,Marius Paraoan,Carlos Pastor,Enrique Pastor,Dimitar Penchev,Miguel Pera,Sharaf Karim Perdawood,Rodrigo Oliva Perez,Roberto Persiani,Frank Pfeffer,P Terry Phang,Andrea Pichetto,Yves Pirenne,Peter Pockney,Karl de Pooter,Eligijus Poskus,Imma Pros,Nirooshun Rajendran,Manoj J Raval,Daniela Rega,Rocco Ricciardi,Wouter van Riel,Frederic Ris,Stefan Riss,Timothy Alexander Rockall,Luis Romagnolo,Juan Manuel Romero-Marcos,Paulo Roquete,Gustavo Rossi,Marcos Gomez Ruiz,Evgeny Rybakov,Yoshiharu Sakai,Andrea Scala,Monica Millan Scheiding,Gerald Monica Millan,Gustavo Seva-Pereira,Raffaella Sguinzi,Irshad A Shaikh,Mostafa Shalaby,Abhiram Sharma,Colin Sietses,Pierpaolo Sileri,Vicente Simo,Baljit Singh,Alistair Slesser,Dae Kyung Sohn,Meindert Sosef,Claudio Soravia,Christopher Speakman,Antonino Spinelli,Frank van Sprundel,Franky van Steenkiste,Andrew R L Stevenson,Anton Stift,P Storms,Peter Studer,Aaldert Konraad Talsma,Pieter J Tanis,Patricia Tejedor,Antonio la Terra,Jared Torkington,Marta Jimenez Toscano,Peter Tschann,Jean-Jacques Tuech,Jurriaan Tuynman,George Tzovaras,Giampaolo Ugolini,Francesc Vallribera,Filip Vanrykel,Stephan Vorburger,Michael Warner,Oliver J Warren,Satish Warrier,Janindra Warusavitarne,Henk Wegstapel,Helmut Weiss,Jacques-Alain Witzig,Torsten Wolff,Albert Wolthuis,Linus Wu,Greg Wynn,Zhang Zhongtao,Urs Zingg,Dorin Ziyaie

DOI: https://doi.org/10.1097/SLA.0000000000003516

Abstract:Objective: The aim of this study was to determine the incidence of, and preoperative risk factors for, positive circumferential resection margin (CRM) after transanal total mesorectal excision (TaTME). Background: TaTME has the potential to further reduce the rate of positive CRM for patients with low rectal cancer, thereby improving oncological outcome. Methods: A prospective registry-based study including all cases recorded on the international TaTME registry between July 2014 and January 2018 was performed. Endpoints were the incidence of, and predictive factors for, positive CRM. Univariate and multivariate logistic regressions were performed, and factors for positive CRM were then assessed by formulating a predictive model. Results: In total, 2653 patients undergoing TaTME for rectal cancer were included. The incidence of positive CRM was 107 (4.0%). In multivariate logistic regression analysis, a positive CRM after TaTME was significantly associated with tumors located up to 1 cm from the anorectal junction, anterior tumors, cT4 tumors, extra-mural venous invasion (EMVI), and threatened or involved CRM on baseline MRI (odds ratios 2.09, 1.66, 1.93, 1.94, and 1.72, respectively). The predictive model showed adequate discrimination (area under the receiver-operating characteristic curve >0.70), and predicted a 28% risk of positive CRM if all risk factors were present. Conclusion: Five preoperative tumor-related characteristics had an adverse effect on CRM involvement after TaTME. The predicted risk of positive CRM after TaTME for a specific patient can be calculated preoperatively with the proposed model and may help guide patient selection for optimal treatment and enhance a tailored treatment approach to further optimize oncological outcomes.